The diabetogenic action of statins-mechanisms and clinical implications

Nature Reviews Endocrinology

Volumn 12, Issue 2, 2016, Pages 99-110

  Betteridge, D John ^a   Carmena, Rafael ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; DEXAMETHASONE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ISOBUTYLMETHYLXANTHINE; LIPID; MEVINOLIN; NICOTINIC ACID; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANTIDIABETIC ACTIVITY; APOPTOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC PATIENT; DIET; DISEASE DURATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCEMIC INDEX; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MENDELIAN RANDOMIZATION ANALYSIS; META ANALYSIS; METABOLIC SYNDROME X; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; POST HOC ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEEDING BEHAVIOR; GENETICS; RISK REDUCTION; SECONDARY PREVENTION;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FOOD HABITS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IN VITRO TECHNIQUES; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MENDELIAN RANDOMIZATION ANALYSIS; RISK FACTORS; RISK REDUCTION BEHAVIOR; SECONDARY PREVENTION;

EID: 84955193209     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2015.194     Document Type: Review

References (107)

1. Endo, A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33, 1569-1582 (1992).
2. Goldstein, J. L. & Brown, M. S. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 29, 431-438 (2009).
3. Brown, M. S. & Goldstein, J. L. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331-340 (1997).
4. Hunninghake, D. B. HMG-CoA reductase inhibitors. Curr. Opin. Lipidol. 3, 22-28 (1992).
5. Slater, E. E. & MacDonald, J. S. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Drugs 36 (Suppl. 3), 72-82 (1988).
6. [No authors listed] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
7. Baigent, C. et al. Efficacy and safety of cholesterollowering treatment; prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366, 1276-1278 (2005).
8. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 371, 117-125 (2008).
9. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet 376, 1670-1681 (2010).
10. Cholesterol Treatment Trialists' (CTT) Collaboration. The effects of lowering LDL-cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomized trials. Lancet 380, 581-590 (2012).
11. Taylor, F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD004816. http://dx.doi.org/10.1002/14651858.CD004816.pub5.
12. Armitage, J. The safety of statins in clinical practice. Lancet 370, 1781-1790 (2007).
13. Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
14. FDA. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. FDA [online], http://www.fda.gov/drugs/ drugsafety/ucm293101.htm (2012).
15. Freeman, D. J. et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103, 357-362 (2001).
16. Coleman, C. I., Reinhart, K., Kluger, J. & White, C.M. The effect of statins on the development of new-onset type 2 diabetes: A meta-analysis of randomized controlled trials. Curr. Med. Res. Opin. 24, 1359-1362 (2008).
17. Sattar, N. et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 375, 735-742 (2010).
18. Shepherd, J. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial. Lancet 360, 1623-1630 (2002).
19. Preiss, D. et al. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: A meta-analysis. JAMA 305, 2556-2564 (2011).
20. Waters, D. D. et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J. Am. Coll. Cardiol. 61, 148-152 (2013).
21. Rajpathak, S. N. et al. Statin therapy and risk of developing type 2 diabetes: A meta-analysis. Diabetes Care 32, 1924-1929 (2009).
22. Dormuth, C. R. et al. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 348, g3244 (2014).
23. Mora, S. et al. Statins for the primary prevention of cardiovascular events in women with elevated highsensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 121, 1069-1077 (2010).
24. Chan, D. C. & Watts, G. F. Dyslipidemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opin. Pharmacother. 12, 13-30 (2011).
25. Culver, A. L. et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch. Intern. Med. 172, 144-152 (2012).
26. Ruscica, M., Macchi, C., Morlotti, B., Sirtori, C.R. & Magni, P. Statin therapy and related risk of newonset type 2 diabetes mellitus. Eur. J. Intern. Med. 25, 401-406 (2014).
27. Sattar, N. A. et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler. Suppl. 15, 1-15 (2014).
28. Sekhar, M. S. & Unnikrishnan, M. K. South-Asian population has a higher likelihood for diabetes risk for statins regardless of potency. Med. Hypotheses 84, 283-284 (2015).
29. Waters, D. D. et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized trials. J. Am. Coll. Cardiol. 57, 1535-1545 (2011).
30. Ridker, P. M. et al. Cardiovascular benefits and diabetes risk of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380, 565-571 (2012).
31. Arnaboldi, L. & Corsini, A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler. Suppl. 16, 1-27 (2015).
32. Chan, D. C., Pang, J. & Watts, G. F. Pathogenesis and management of the diabetogenic effect of statins: A role for adiponectin and coenzyme Q10. Curr. Atheroscler. Rep. 17, 472 (2015).
33. Sabatine, M. S. et al. High-dose atorvastatin associated with worse glycemic control: A PROVE-IT TIMI 22 sub study [abstract]. Circulation 110, S834 (2004).
34. Sasaki, J., Iwashita, M. & Kono, M. Statins: beneficial or adverse for glucose metabolism. J. Atheroscler. Thromb. 13, 123-129 (2006).
35. Chapman, M. J. et al. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPTAIN and PREVAIL-US studies. Curr. Med. Res. Opin. 30, 775-784 (2014).
36. Cederberg, H. et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6 year follow-up study of the METSIM cohort. Diabetologia 58, 1109-1117 (2015).
37. Yamakawa, T. et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J. Atheroscler. Thromb. 15, 269-275 (2008).
38. Teramoto, T. et al. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin. Pharmacother. 11, 817-828 (2010).
39. Odawara, M. et al. Pitavastatin for the delay or prevention of diabetes development in individuals with impaired glucose tolerance. American Diabetes Association [online], http://www.abstractsonline.com/ plan/ViewAbstract.aspx?mID=3217&sKey= 0687e7c8-c97d-442b-92ec-ae505e051854&cKey= b4ea3c2f-884e-44d3-b9b1-86846eadbd1d&mKey= 89918d6d-3018-4ea9-9d4f-711f98a7ae5d (2013).
40. Cho, Y. et al. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors. Metabolism 64, 482-488 (2015).
41. Vallejo-Vaz, A. J. et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis 241, 409-418 (2015).
42. Erqou, S., Lee, C. C. & Adler, A. I. Statins and glycemic control in individuals with diabetes: A systematic review and meta-analysis. Diabetologia 57, 2444-2452 (2014).
43. Ray, K. K. et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomized controlled trials. Lancet 373, 1765-1772 (2009).
44. Colhoun, H. M. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebocontrolled trial. Lancet 364, 685-696 (2004).
45. Swerdlow, D. I. & Sattar, N. A dysglycaemic effect of statins in diabetes: relevance to clinical practice? Diabetologia 57, 2433-2435 (2014).
46. van de Woestijne, A. P., van der Graaf, Y., Westerink, J., Nathoe, H. M. & Visseren, F. L. Effect of statin therapy on incident type 2 diabetes mellitus in patients with clinically manifest vascular disease. Am. J. Cardiol. 115, 441-446 (2015).
47. Skoumas, J. et al. Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia. Atherosclerosis 237, 140-145 (2014).
48. Panz, V., Immelman, A., Paiker, J., Pilcher, G. & Raal, F. High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia. Metab. Syndr. Relat. Disord. 10, 351-357 (2012).
49. Besseling, J., Kastelein, J. J., Defesche, J. C., Hutton, B. A. & Hovingh, G. K. Association between familial hypercholesterolaemia and prevalence of type 2 diabetes mellitus. JAMA 313, 1029-1036 (2015).
50. Swerdlow, D. J. et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 385, 351-361 (2015).
51. Czech, M. P. Cellular basis of insulin insensitivity in large rat adipocytes. J. Clin. Invest. 57, 1523-1532 (1976).
52. Olefsky, J. M. Mechanisms of decreased insulin responsiveness of large adipocytes. Endocrinology 100, 1169-1177 (1977).
53. Friedman, J. M. Obesity in the new millennium. Nature 404, 632-634 (2000).
54. Kovanen, P. T., Nikkila, E. A. & Miettinen, T. A. Regulation of cholesterol synthesis and storage in fat cells. J. Lipid Res. 16, 211-223 (1975).
55. Krause, B. R. & Hartman, A. D. Adipose tissue and cholesterol metabolism. J. Lipid Res. 25, 97-110 (1984).
56. Van Harmelen, V. et al. Increased adipose angiotensinogen gene expression in human obesity. Obes. Res. 8, 337-341 (2000).
57. Hotamisligil, G. S., Shargill, N. S. & Spiegelman, B. M. Adipose expression of tumour necrosis factor-α: A direct role in obesity-linked insulin resistance. Science 259, 87-91 (1993).
58. Fried, S. K., Bunkin, D. A. & Greenberg, S. A. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6, depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 83, 847-850 (1998).
59. Le Lay, S. et al. Cholesterol, a cell size-dependent signal that regulates glucose metabolism and gene expression in adipocytes. J. Biol. Chem. 276, 16904-16910 (2001).
60. Parpal, S., Karlsson, M., Thorn, H. & Stralfors, P. Cholesterol depletion disrupts caveolae and insulin receptor signalling for metabolic control via insulin receptor substrate-1 but not for mitogen-activated protein kinase control. J. Biol. Chem. 276, 9670-9678 (2001).
61. Gustavasson, J. et al. Localization of the insulin receptor in caveolae of adipocyte plasma membrane. FASEB J. 13, 1961-1971 (1999).
62. Chamberlain, L. H. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett. 507, 357-361 (2001).
63. Takaguri, A., Sotoh, K., Itagaki, M., Tokumitsu, Y. & Ichihara, K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L-1 adipocytes. J. Pharmacol. Sci. 107, 80-89 (2008).
64. Ganesan, S. & Ito, M. K. Coenzyme Q10 ameliorates the reduction in GLUT4 transporter expression induced by simvastatin in 3T3-L1 adipocytes. Metab. Syndr. Relat. Disord. 11, 251-255 (2013).
65. Donath, M. Y. & Shoelson, S. E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11, 98-107 (2011).
66. Shoelson, S. E., Lee, J. & Goldfine, A. B. Inflammation and insulin resistance. J. Clin. Invest. 116, 1793-1801 (2006).
67. Jager, J., Grémeaux, T., Cormont, M., Le Marchand-Brustel, Y. & Tanti, J. F. Interleukin-β-induced insulin resistance in adipocytes through downregulation of insulin receptor substrate-1 expression. Endocrinology 148, 241-251 (2007).
68. Lagathu, C. Long term treatment with interleukin-1β induces insulin resistance in murine and human adipocytes. Diabetologia 49, 2162-2173 (2006).
69. Vandanmagsar, B. et al. The NLRP3 inflammasone instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179-188 (2011)
70. Stienstra, R. et al. The inflammasone-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12, 593-605 (2010).
71. Lee H.M. et al. Upregulated NLRP3 inflammasome in patients with type 2 diabetes. Diabetes 62, 194-204 (2013).
72. Henriskbo, B. D. et al. Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance. Diabetes 63, 3742-3747 (2014).
73. Baker, W. L., Talati, R., White, C. M. & Coleman, C. I. Differing effects on insulin sensitivity in non-diabetics: A systematic review and meta-analysis. Diabetes Res. Clin. Pract. 87, 98-107 (2010).
74. Kadowaki, T. et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes and the metabolic syndrome. J. Clin. Invest. 116, 1784-1792 (2006).
75. Li, S., Shin, H. J., Ding, E. L. & van Dam, R. M. Adiponectin levels and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 302, 179-188 (2009).
76. Hara, K. et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51, 536-540 (2002).
77. Kondo, H. et al. Association of adiponectin mutation with type 2 diabetes: A candidate gene for the insulin resistance syndrome. Diabetes 51, 2325-2328 (2002).
78. Strumvoll, M. et al. Association of the T.G polymorphism in adiponectin (exon 20 with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 51,37-41 (2002).
79. Roehrich, M. E. et al. Insulin-secreting .cell dysfunction induced by human lipoproteins. J. Biol. Chem. 278, 18368-18375 (2003).
80. Hao, M., Head, W. S., Gunawardeana, S. C., Hasty, A. H. & Piston, D. W. Direct effect of cholesterol on insulin secretion: A novel mechanism for pancreatic .cell dysfunction. Diabetes 56, 2328-2338 (2007).
81. Rutti, S. et al. Low and high density lipoproteins modulate function, apoptosis and proliferation of primary human and murine pancreatic .cells. Endocrinology 150, 4521-4530 (2009).
82. Kruit, J. K., Brunham, L. R., Verchere, C. B. & Hayden, M. R. HDL and LDL cholesterol significantly influence .cell function in type 2 diabetes mellitus. Curr. Opin. Lipidol. 21, 178-185 (2010).
83. Brunham, L. R. et al. .cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 13, 340-347 (2007).
84. Fryirs, M. A. et al. Effects of high-density lipoproteins on pancreatic .cell insulin secretion. Arterioscler. Thromb. Vasc. Biol. 30, 1642-1648 (2010).
85. Sturek, J. M. et al. An intracellular role for ABCG1.mediated cholesterol transport in the regulated secretory pathway of mouse pancreatic cells. J. Clin. Invest. 120, 2575-2589 (2010).
86. Bogan, J. S., Xu, Y. & Hao, M. Cholesterol accumulation increases insulin granule size and impairs membrane trafficking. Traffic 13, 1466-1480 (2012).
87. Metz, S. A., Rabaglia, M. E., Stock, J. B. & Kowluru, A. Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. Biochem. J. 295, 31-40 (1993).
88. Li, G., Regazzi, R., Roche, E. & Wollheim, C. B. Blockade of mevalonate production by lovastatin attenuates bombesin and vasopressin potentiation of nutrient-induced insulin secretion in HIT.T15 cells. Biochem. J. 289, 379-385 (1993).
89. Yada, T., Nakata, M., Shiraishi, T. & Kakei, M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L.type Ca2+ channels in rat islet .cells. Br. J. Pharmacol. 126, 1205-1213 (1999).
90. Zhou, J. et al. Effect of glucose metabolism in mouse MIN6 cells. J. Diabetes Res. 2014, 376570 (2014).
91. Chen, Z. et al. Atorvastatin helps preserve pancreatic cell function in obese C57BL/6 J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress. Lipids Health Dis. 13, 98 (2014).
92. Mita, T. et al. Preferable effect of pravastatin compared to atorvastatin on cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocr. J. 54, 441-447 (2007).
93. Stumvoll, M. et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23, 295-301 (2000).
94. Matsuda, M. & DeFronzo, R. A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycaemic insulin clamp. Diabetes Care 22, 1462-1470 (1999).
95. Larsen, S. et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. JAMA 61, 44-53 (2013).
96. Banach, M. et al. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr. Pharm. Des. 19, 4904-4912 (2013).
97. Barylski, M. et al. Statins and new-onset diabetes. Curr. Pharm. Des. 20, 3657-3664 (2014).
98. Sattar, N. & Taskinen, M. R. Statins are diabetogenic-myth or reality? Atheroscler. Suppl. 13, 1-10 (2012).
99. Lindstrom, J. et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3 year results on diet and physical activity. Diabetes Care 26, 3230-3236 (2003).
100. Lindstrom, J. et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368, 1673-1679 (2006).
101. Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
102. Diabetes Prevention Program Research Group. The 10 year cost-effectiveness of lifestyle and metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 35, 723-730 (2012).
103. Fradkin, J. E., Roberts, B. T. & Rodgers, G. P. What's preventing us from preventing type 2 diabetes? N. Engl. J. Med. 367, 1177-1179 (2012).
104. Nielsen, S. F. & Nordestgaard, B. G. Statin use before diabetes diagnosis and risk of microvascular disease: A nationwide nested matched study. Lancet Diabetes Endocrinol. 2, 894-900 (2014).
105. Chen, S. C & Tseng, C. H. Dyslipidaemia, kidney disease and cardiovascular disease in diabetic patients. Rev. Diabet. Stud. 10, 88-100 (2013).
106. Zafrir, B. & Jain, M. Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. Cardiovasc. Drugs Ther. 28, 361-377 (2014).
107. Tennebaum, A. & Fisman, E. Z. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc. Diabetol. 11, 140-149 (2012).